ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Maryland » Cardiovascular Disease

Top Cardiovascular Disease Prescribers in Maryland

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
MYUNG PARK M.D.

Cardiovascular Disease

663

$1.35M

79
48 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

62%
prescriptions for brand name drugs

Avg: 28%

$2034
Average prescription price

Avg: $84

GAUTAM RAMANI MD

Cardiovascular Disease

758

$512K

93
50 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

41%
prescriptions for brand name drugs

Avg: 28%

$676
Average prescription price

Avg: $84

RICHARD SCHOENFELD M.D.

Cardiovascular Disease

273

$54.9K

33
28 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

45%
prescriptions for brand name drugs

Avg: 28%

$201
Average prescription price

Avg: $84

STACY FISHER M.D.

Cardiovascular Disease

2,145

$366K

231
177 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

37%
prescriptions for brand name drugs

Avg: 28%

$171
Average prescription price

Avg: $84

JULIA WEN M.D.

Cardiovascular Disease

1,867

$302K

152
143 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

48%
prescriptions for brand name drugs

Avg: 28%

$162
Average prescription price

Avg: $84

STEVEN KAUFMAN M.D.

Cardiovascular Disease

959

$128K

108
103 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

44%
prescriptions for brand name drugs

Avg: 28%

$133
Average prescription price

Avg: $84

ALLEN NIMETZ M.D.

Cardiovascular Disease

1,985

$262K

177
169 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

42%
prescriptions for brand name drugs

Avg: 28%

$132
Average prescription price

Avg: $84

RICHARD RUBIN M.D.

Cardiovascular Disease

1,457

$189K

188
180 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

44%
prescriptions for brand name drugs

Avg: 28%

$130
Average prescription price

Avg: $84

CYNTHIA CRAWFORD-GREEN M.D.

Cardiovascular Disease

2,020

$261K

149
98 are 65+

10%
patients receiving schedule two controlled substances

Avg: 0%

18%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

40%
prescriptions for brand name drugs

Avg: 28%

$129
Average prescription price

Avg: $84

RAYMON NELSON MD

Cardiovascular Disease

5,269

$674K

191
147 are 65+

10%
patients receiving schedule two controlled substances

Avg: 0%

14%
patients receiving schedule three controlled substances

Avg: 0%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

38%
prescriptions for brand name drugs

Avg: 28%

$128
Average prescription price

Avg: $84

JORGE SECADA-LOVIO M.D.

Cardiovascular Disease

1,100

$139K

135
127 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

35%
prescriptions for brand name drugs

Avg: 28%

$127
Average prescription price

Avg: $84

ROGER BLUMENTHAL M.D.

Cardiovascular Disease

853

$106K

160
147 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

36%
prescriptions for brand name drugs

Avg: 28%

$125
Average prescription price

Avg: $84

CONOR LUNDERGAN M.D.

Cardiovascular Disease

1,341

$167K

170
155 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 28%

$124
Average prescription price

Avg: $84

STEVEN TEE M.D.

Cardiovascular Disease

6,571

$815K

303
241 are 65+

9%
patients receiving schedule two controlled substances

Avg: 0%

14%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

30%
prescriptions for brand name drugs

Avg: 28%

$124
Average prescription price

Avg: $84

ALI TABRIZCHI D.O.

Cardiovascular Disease

2,147

$262K

394
349 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 28%

$122
Average prescription price

Avg: $84

ROBERT DIBIANCO M.D.

Cardiovascular Disease

2,322

$281K

283
259 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

39%
prescriptions for brand name drugs

Avg: 28%

$121
Average prescription price

Avg: $84

SAMUEL FOSTER MD

Cardiovascular Disease

1,083

$129K

155
132 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

35%
prescriptions for brand name drugs

Avg: 28%

$119
Average prescription price

Avg: $84

CARL FRIEDMAN M.D.

Cardiovascular Disease

2,792

$326K

197
178 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 28%

$117
Average prescription price

Avg: $84

SHAHID SAEED MD

Cardiovascular Disease

1,383

$158K

225
204 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

37%
prescriptions for brand name drugs

Avg: 28%

$114
Average prescription price

Avg: $84

JONATHAN ALTSCHULER M.D.

Cardiovascular Disease

698

$79.5K

127
116 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

36%
prescriptions for brand name drugs

Avg: 28%

$114
Average prescription price

Avg: $84

JOSHUA YAMAMOTO M.D.

Cardiovascular Disease

1,436

$164K

191
185 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

36%
prescriptions for brand name drugs

Avg: 28%

$114
Average prescription price

Avg: $84

DEBORAH BARBOUR M.D.

Cardiovascular Disease

1,333

$151K

127
120 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

36%
prescriptions for brand name drugs

Avg: 28%

$113
Average prescription price

Avg: $84

JOSEPH VASSALLO M.D.

Cardiovascular Disease

2,284

$257K

227
217 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

40%
prescriptions for brand name drugs

Avg: 28%

$113
Average prescription price

Avg: $84

DAVID JACKSON M.D.

Cardiovascular Disease

2,292

$255K

303
274 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

37%
prescriptions for brand name drugs

Avg: 28%

$111
Average prescription price

Avg: $84

ROBERT GALLINO M.D.

Cardiovascular Disease

1,077

$119K

178
157 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

46%
prescriptions for brand name drugs

Avg: 28%

$111
Average prescription price

Avg: $84

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank